HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

HERON THERAPEUTICS, INC. /DE/

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$0.36−0.00 (-0.03%)

Close on Oct 19, 2026

Market cap: $68.69M
P/E (TTM): –
Dividend yield: –

HERON THERAPEUTICS, INC. /DE/ cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Depreciation & Amortization	2.31	2.49	2.90	2.89	3.02	2.85	2.04	1.51	1.53	1.10	0.73	0.58	0.33	0.20	0.18	0.23	0.36
Stock-Based Compensation	10	13	33	43	47	50	51	33	31	26	14	8.07	11	5.73	1.89	1.75	1.14
Change in Accounts Receivable	-11	-19	-8.09	-17	6.35	-1.97	25	-23	-40	-1.96	–	–	–	–	0.11	-0.06	0.14
Change in Inventory	-31	-11	12	-6.19	-6.48	-17	14	-29	-4.77	-5.34	–	–	–	–	–	–	–
Change in Accounts Payable	-2.72	8.47	0.02	-0.58	3.28	-2.23	-14	-1.91	12	3.51	0.75	1.29	-0.43	0.98	0.47	0.00	-0.18
Change in Unearned Revenue	–	–	–	–	–	–	–	–	1.66	1.10	–	–	–	–	-0.27	-0.09	-0.64
Operating Cash Flow	-28	-23	-59	-147	-203	-185	-125	-192	-170	-134	-79	-60	-41	-17	-7.72	-5.48	-11
Capital Expenditures	-0.32	-1.71	-1.55	-1.83	-3.02	-6.81	-7.15	-9.17	-2.55	-3.14	-1.09	-1.44	-1.69	-0.97	-0.51	-0.08	0.00
Sale of Property, Plant & Equipment	0.10	0.03	0.01	0.23	0.03	–	–	0.03	0.08	–	0.24	–	–	–	–	–	–
Purchase of Investments	-51	-103	-88	-146	-129	-134	-477	-497	-122	-43	-56	–	–	–	–	–	–
Sale & Maturity of Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.61
Investing Cash Flow	16	19	18	-3.32	33	209	-22	-279	7.74	15	-57	-1.44	-1.69	-0.97	-0.51	-0.08	0.61
Stock Issued	18	–	30	75	–	–	162	363	306	–	–	59	58	50	–	–	–
Debt Repaid	–	–	–	–	–	–	–	-25	-25	–	–	–	–	–	–	–	–
Financing Cash Flow	14	0.94	54	75	156	9.11	186	358	294	57	138	62	61	54	24	0.08	8.01
Net Change in Cash	2.85	-2.88	13	-75	-15	33	40	-113	131	-62	2.51	0.39	19	36	16	-5.48	-2.37
Free Cash Flow	-28	-24	-60	-149	-206	-192	-132	-201	-173	-137	-80	-62	-42	-18	-8.23	-5.56	-11
Interest Paid	6.51	4.86	3.06	2.25	1.24	–	–	1.18	2.79	1.62	0	0	0	0	0.00	0.00	0.00

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 70.1%
Operating margin: -7.2%
Net margin: -22.5%
Return on equity, FY2025: 209.1%

Financial strength

Current ratio: 2.49
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 22.5%

Valuation

P/E ratio: –
Price to sales: 0.45
Price to book: 9.94
Dividend yield: –